KRAS testing of patients with metastatic colorectal cancer in a community-based oncology setting: A retrospective database analysis

Journal of Experimental and Clinical Cancer Research

Volumn 34, Issue 1, 2015, Pages

  Carter, Gebra Cuyun ^a   Landsman Blumberg, Pamela B ^b   Johnson, Barbara H ^b   Juneau, Paul ^b   Nicol, Steven J ^a   Li, Li ^a   Shankaran, Veena ^c  

^a ELI LILLY AND COMPANY   (United States)

^b IBM WATSON HEALTH   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

KRAS; KRAS testing; mCRC; Metastatic colorectal cancer

Indexed keywords

CETUXIMAB; K RAS PROTEIN; PANITUMUMAB; KRAS PROTEIN, HUMAN; PROTEIN P21;

ADULT; ALGORITHM; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GRADING; CANCER LOCALIZATION; CANCER PATIENT; COMORBIDITY; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; ICD-9-CM; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; PREDICTIVE VALUE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; ADOLESCENT; AGED; COLORECTAL NEOPLASMS; COMMUNITY CARE; FACTUAL DATABASE; GENETIC SCREENING; GENETICS; GENOTYPE; METASTASIS; MIDDLE AGED; ODDS RATIO; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; COMMUNITY HEALTH SERVICES; DATABASES, FACTUAL; FEMALE; GENETIC TESTING; GENOTYPE; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM METASTASIS; ODDS RATIO; PROTO-ONCOGENE PROTEINS P21(RAS); RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84961314274     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/s13046-015-0146-5     Document Type: Article

References (23)

1. American Cancer Society: Cancer Facts & Figures 2013 [ http://www.cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2013 ]
2. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277-300.
3. Monzon FA, Ogino S, Hammond ME, Halling KC, Bloom KJ, Nikiforova MN. The role of KRAS mutation testing in the management of patients with metastatic colorectal cancer. Arch Pathol Lab Med. 2009;133:1600-6.
4. Benson AB III: Epidemiology, disease progression, and economic burden of colorectal cancer. J Manag Care Pharm 2007,13 (6 Suppl C):S5-S18.
5. Avastin [prescribing information]. South San Francisco, CA: Genentech, Inc; 2013.
6. Erbitux [prescribing information]. Branchburg, NJ: ImClone LLC a wholly-owned subsidiary of Eli Lilly and Company, and Bristol-Myers Squibb Company; 2013.
7. Vectibix [prescribing information]. Thousand Oaks, CA: Amgen Inc; 2014.
8. Soulières D, Greer W, Magliocco AM, Huntsman D, Young S, Tsao MS, et al. KRAS mutation testing in the treatment of metastatic colorectal cancer with anti-EGFR therapies. Curr Oncol. 2010;17 Suppl 1:S31-40.
9. Lièvre A, Artru P, Guiu M, Laurent-Puig P, Merlin JL, Sabourin JC, et al. The KRAS mutation detection within the initial management of patients with metastatic colorectal cancer: a status report in France in 2011. Eur J Cancer. 2013;49:2126-33.
10. Tonini G, Imperatori M, Vincenzi B, Frezza AM, Santini D. Rechallenge therapy and treatment holiday: different strategies in management of metastatic colorectal cancer. J Exp Clin Cancer Res. 2013;32:92.
11. Xu JM, Liu XJ, Ge FJ, Lin L, Wang Y, Sharma MR, et al. KRAS mutations in tumor tissue and plasma by different assays predict survival of patients with metastatic colorectal cancer. J Exp Clin Cancer Res. 2014;33:104.
12. National Comprehensive Cancer Network. Clinical practice guidelines in oncology (NCCN Guidelines), colon cancer. Fort Washington: NCCN; 2008.
13. Landsman-Blumberg PB, Carter GG, Johnson BH, Sedgley R, Nicol SJ, Li L, et al. Metastatic colorectal cancer treatment patterns according to kirsten rat sarcoma viral oncogene homolog genotype in U.S. Community-based oncology practices. Clin Colorectal Cancer. 2014;13:178-84.
14. National Comprehensive Cancer Network. Clinical practice guidelines in oncology (NCCN Guidelines), colon cancer. Fort Washington: NCCN; 2012.
15. Tan C, Du X. KRAS mutation testing in metastatic colorectal cancer. Word J Gastroenterol. 2012;18:5171-80.
16. Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, Hayes DF, et al. American society of clinical oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol. 2009;27:2091-6.
17. Abrams TA, Meyer G, Schrag D, Meyerhardt JA, Moloney J, Fuchs CS: Chemotherapy usage patterns in a US-wide cohort of patients with metastatic colorectal cancer. J Natl Cancer Inst 2014, 106:djt371.
18. Ciardiello F, Tejpar S, Normanno N, Mercadante D, Teague T, Wohlschlegel B, et al. Uptake of KRAS mutation testing in patients with metastatic colorectal cancer in Europe, Latin America and Asia. Target Oncol. 2011;6:133-45.
19. Webster J, Kauffman TL, Feigelson HS, Pawloski PA, Onitilo AA, Potosky AL, et al. KRAS testing and epidermal growth factor receptor inhibitor treatment for colorectal cancer in community settings. Cancer Epidemiol Biomarkers Prev. 2013;22:91-101.
20. Miller PJ, Walker MS, Landsman-Blumberg P, Cuyun Carter G: Using text mining of electronic medical records to identify KRAS testing status in mCRC patients [abstract]. Value Health 2013, 16:A21.
21. Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmueller J, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Hielscher J, Scholz M, Mueller S, Schaefer B, Modest DP, Jung A, Stintzing S: Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS wild-type metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3) [abstract]. J Clin Oncol 2013, 31(18 suppl):Abstract LBA3506.
22. Hess GP, Wang PF, Quach D, Barber B, Zhao Z. Systemic therapy for metastatic colorectal cancer: patterns of chemotherapy and biologic therapy use in US medical oncology practice. J Oncol Pract. 2010;6:301-7.
23. Kim GP, Sargent DJ, Mahoney MR, Rowland Jr KM, Philip PA, Mitchell E, et al. Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841. J Clin Oncol. 2009;27:2848-54.